"Schwarz, Ji\u0159\u00ED" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "Esenci\u00E1ln\u00ED trombocytemie (ET) nen\u00ED \u010Dast\u00E9 onemocn\u011Bn\u00ED (incidence je asi 0.1-1.5 p\u0159\u00EDpad\u016F na 100000 osob). Nov\u00E9 p\u0159\u00EDstupy a mo\u017Enosti pokroku p\u0159i standardn\u00ED p\u00E9\u010Di ale zp\u011Btn\u011B vy\u017Eaduj\u00ED odpov\u011Bdn\u00FD a systematick\u00FD p\u0159\u00EDstup a proto\u017Ee se vyskytuj\u00ED jak ve vztahu k diagnostice tak k l\u00E9\u010Db\u011B, je nutn\u00E9 se pat\u0159i\u010Dn\u011B t\u00EDmto probl\u00E9m zab\u00FDvat. Je zde \u0159ada aspekt\u016F, kter\u00E9 evokuj\u00ED kontroverze v r\u00E1mci diagnostiky a diferenci\u00E1ln\u00ED diagn\u00F3zy - nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED v\u011Bc je, zda se po\u017Eaduje histologick\u00E9 vy\u0161et\u0159en\u00ED kostn\u00ED d\u0159en\u011B, nebo ne, a jak organizovat p\u00E9\u010Di o pacienty. To v\u0161e se t\u00FDk\u00E1 nejen z\u00E1kladn\u00ED trombocytopenie, ale tak\u00E9 na myeloproliferativn\u00EDch chorob souvisej\u00EDc\u00EDch s jin\u00FDmi myeloproliferativn\u00EDmi chorobami (MPO-T). P\u0159ilo\u017Een\u00E9 doporu\u010Den\u00E9 pokyny postup\u016F by mohly slou\u017Eit jako vod\u00EDtko p\u0159i probl\u00E9mech uveden\u00FDch bez omezen\u00ED prostoru pro disputace." . . "Esenci\u00E1ln\u00ED trombocytemie (ET) nen\u00ED \u010Dast\u00E9 onemocn\u011Bn\u00ED (incidence je asi 0.1-1.5 p\u0159\u00EDpad\u016F na 100000 osob). Nov\u00E9 p\u0159\u00EDstupy a mo\u017Enosti pokroku p\u0159i standardn\u00ED p\u00E9\u010Di ale zp\u011Btn\u011B vy\u017Eaduj\u00ED odpov\u011Bdn\u00FD a systematick\u00FD p\u0159\u00EDstup a proto\u017Ee se vyskytuj\u00ED jak ve vztahu k diagnostice tak k l\u00E9\u010Db\u011B, je nutn\u00E9 se pat\u0159i\u010Dn\u011B t\u00EDmto probl\u00E9m zab\u00FDvat. Je zde \u0159ada aspekt\u016F, kter\u00E9 evokuj\u00ED kontroverze v r\u00E1mci diagnostiky a diferenci\u00E1ln\u00ED diagn\u00F3zy - nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED v\u011Bc je, zda se po\u017Eaduje histologick\u00E9 vy\u0161et\u0159en\u00ED kostn\u00ED d\u0159en\u011B, nebo ne, a jak organizovat p\u00E9\u010Di o pacienty. To v\u0161e se t\u00FDk\u00E1 nejen z\u00E1kladn\u00ED trombocytopenie, ale tak\u00E9 na myeloproliferativn\u00EDch chorob souvisej\u00EDc\u00EDch s jin\u00FDmi myeloproliferativn\u00EDmi chorobami (MPO-T). P\u0159ilo\u017Een\u00E9 doporu\u010Den\u00E9 pokyny postup\u016F by mohly slou\u017Eit jako vod\u00EDtko p\u0159i probl\u00E9mech uveden\u00FDch bez omezen\u00ED prostoru pro disputace."@cs . "Pytl\u00EDk, R." . "guidelines; thrombocythemia; therapy"@en . . . "1"^^ . "Doporu\u010Den\u00FD postup diagnostiky a terapie esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED choroby."@cs . . "Doubek, M." . . "Penka, M." . "Dul\u00ED\u010Dek, P." . "0042-773X" . . "Practice guidelines for diagnosis and therapy of essential thrombocytaemia and thrombocytaemia associated with other myeloproliferative diseases"@en . "CZ - \u010Cesk\u00E1 republika" . . . "518655" . "Doporu\u010Den\u00FD postup diagnostiky a terapie esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED choroby."@cs . . "[81DE9A3F61BC]" . "RIV/00023736:_____/05:00006033" . . "Practice guidelines for diagnosis and therapy of essential thrombocytaemia and thrombocytaemia associated with other myeloproliferative diseases"@en . "Doporu\u010Den\u00FD postup diagnostiky a terapie esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED choroby." . "RIV/00023736:_____/05:00006033!RIV09-MZ0-00023736" . . . "6" . "Brychtov\u00E1, Y." . "11"^^ . . "Essential thrombocytaemia (ET) is not a frequent disease (incidence rate is about 0.1-1.5 cases per 100,000 persons) but as new approaches and possibilities advancing the standard care but contrariwise requiring responsible and systematic approach occur both in relationship with diagnosis and with treatment, it is necessary to deal appropriately with this problem. There is a variety of aspects, which evoke controversy within the scope of diagnosis and differential diagnosis - the most important thing is whether the histological examination of bone marrow is required or not and how to organise care of patients. All this relates not only to essential thrombocytopenia but also to myeloproliferative diseases associated with other myeloproliferative diseases at all (MPO-T). Enclosed recommended practice guidelines could help to serve as a guide in problems given without limiting the space for disputation."@en . "S, V" . . . "6"^^ . "Doporu\u010Den\u00FD postup diagnostiky a terapie esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED choroby." . "51" .